Understanding the Mechanism of Cell Death in Gemcitabine Resistant Pancreatic Ductal Adenocarcinoma: A Systems Biology Approach

BACKGROUND: Gemcitabine is the standard chemotherapeutic drug administered in advanced Pancreatic Ductal Adenocarcinoma (PDAC). However, due to drug resistance in PDAC patients, this treatment has become less effective. Over the years, clinical trials for the quest of finding novel compounds that ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Aier, Imlimaong, Varadwaj, Pritish K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327974/
https://www.ncbi.nlm.nih.gov/pubmed/32655287
http://dx.doi.org/10.2174/1389202920666191025102726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327974/
https://www.ncbi.nlm.nih.gov/pubmed/32655287
http://dx.doi.org/10.2174/1389202920666191025102726

Ejemplares similares